Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation
about
sameAs
OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamiliesPediatric Statin Administration: Navigating a Frontier with Limited DataSystems pharmacology uncovers Janus functions of botanical drugs: activation of host defense system and inhibition of influenza virus replication.Simultaneous assessment of uptake and metabolism in rat hepatocytes: a comprehensive mechanistic modelTransport of fluorescent chenodeoxycholic acid via the human organic anion transporters OATP1B1 and OATP1B3.Evaluation of CYP3A-mediated drug-drug interactions with romidepsin in patients with advanced cancer.Identification, Ki determination and CoMFA analysis of nuclear receptor ligands as competitive inhibitors of OATP1B1-mediated estradiol-17beta-glucuronide transportXenobiotic, bile acid, and cholesterol transporters: function and regulation.Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment.Development of a cell-based high-throughput assay to screen for inhibitors of organic anion transporting polypeptides 1B1 and 1B3.Genetic Determinants of the Pharmacokinetic Variability of Rifampin in Malawian Adults with Pulmonary Tuberculosis.Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations.Interaction of three regiospecific amino acid residues is required for OATP1B1 gain of OATP1B3 substrate specificity.The SLCO (former SLC21) superfamily of transporters.Several conserved positively charged amino acids in OATP1B1 are involved in binding or translocation of different substratesImpact of OATP transporters on pharmacokinetics.Pharmacogenetics of OATP (SLC21/SLCO), OAT and OCT (SLC22) and PEPT (SLC15) transporters in the intestine, liver and kidney.Potential role of organic anion transporting polypeptide 1B1 (OATP1B1) in the selective hepatic uptake of hematoporphyrin monomethyl ether isomers.The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications.Complex drug interactions of the HIV protease inhibitors 3: effect of simultaneous or staggered dosing of digoxin and ritonavir, nelfinavir, rifampin, or bupropionEffect of rifampicin on pravastatin pharmacokinetics in healthy subjects.Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes.Practical aspects of transporter model systems: a case study involving SQV.Differential expression of several drug transporter genes in HepG2 and Huh-7 cell lines.Effect of anti-tuberculosis therapy on polymorphic drug metabolizing enzyme CYP2C9 using phenytoin as a probe drug.Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination.Targeted drug delivery to treat pain and cerebral hypoxiaElucidating rifampin's inducing and inhibiting effects on glyburide pharmacokinetics and blood glucose in healthy volunteers: unmasking the differential effects of enzyme induction and transporter inhibition for a drug and its primary metabolite.Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans.Natural polyphenol disposition via coupled metabolic pathways.Targeted disruption of murine organic anion-transporting polypeptide 1b2 (Oatp1b2/Slco1b2) significantly alters disposition of prototypical drug substrates pravastatin and rifampinInduction of hepatic cytochrome P450 enzymes: methods, mechanisms, recommendations, and in vitro-in vivo correlations.Role of OATP transporters in the disposition of drugs.Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors.Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers.The role of transporters in the pharmacokinetics of orally administered drugs.Idiosyncratic Drug-Induced Liver Injury (IDILI): Potential Mechanisms and Predictive Assays.Factors associated with variability in rifampin plasma pharmacokinetics and the relationship between rifampin concentrations and induction of efavirenz clearance.Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects.Pharmacogenetics of drug transporters in the enterohepatic circulation.
P2860
Q27001267-13121C75-5C17-4812-B0B4-6AC9E0813304Q28068014-ACB2770E-91CB-4A05-8165-A9EF4EB88C10Q30423829-17BD9761-8057-4C78-A4B5-441C5A5F9742Q30511951-5DA88952-1BF4-49A5-970E-4289D43BAB70Q33236324-F183DBAB-279E-4678-9A15-D29D77012A5AQ33423486-6BCD50D5-8DFD-43AD-8B7F-A9690AC00415Q33442288-8546C8EE-C901-43C6-8644-0BC4A5E2307BQ33714593-F2E955A2-5F95-4EFA-AE4F-110BA7739C69Q33797850-8D404AF0-6C1D-4427-9678-AC12F4CE0BAFQ33829256-67287890-AC3A-4E4C-A8B4-0CD5D907E7A3Q33843657-5E644563-52CB-4E3F-832D-9B6CA5FA95FCQ34150929-D29B31C1-A3E0-483C-A01E-AF2CF8767574Q34165400-61FCA819-FCF2-412C-9DC5-69B601C65484Q34333710-E70F3E84-678A-4520-9A74-D53B2DF28C5CQ34340098-57FA95A3-4999-4584-A4BF-42A3F41CA55AQ34612244-50EAA195-8349-4C75-B61C-42713B325F98Q34777362-7C894AD5-C166-46A7-886E-B3E6451EB9BCQ35080119-53315E50-2FA9-4C47-B4EE-F975310BC3F7Q35191432-875E42CE-B3BE-44E9-8522-DACBC144C59CQ35776626-96505842-B8DE-4720-9FB5-92A3288F61FBQ35825922-7C33B06C-9395-417E-A61F-D09A7033E166Q35827696-DE6EB280-E1C1-4237-8AE6-AFE0C83F9C04Q35828049-86C414AE-E898-404B-8447-B47F09C72526Q36067365-CE342FC6-433A-4E8A-9ECC-6A13A23D088DQ36313485-1523109A-4757-4608-9841-E5AE47004B5DQ36544966-E7D51697-13A5-4AF9-B7EB-6F36C29344FBQ36591611-B87C24DB-B4DC-41A2-8278-A2F8DAF9C16CQ36639493-BAE5E151-4F02-4A65-B22C-B0885835C0FDQ36687277-4AA688E4-86F8-4F66-B8EB-5A79BED4CCF0Q36835822-63955246-B57E-4FBF-B6D3-BF35991D16C0Q36926314-66E5C3F0-5E24-467E-A253-DA5471C104E2Q36985079-D24CC4C2-E21D-49A7-92A8-C525D11D4219Q37074085-DF7F5A69-C110-461F-A3ED-8798DA611225Q37113947-9D2D6F29-D53E-4D55-A806-706A0220A8B2Q37392745-0C6B0F54-24E1-469F-9A5C-DD06240B6FEFQ37537018-93B1CEFE-52BA-45EC-95DD-420087811A61Q37590883-95768590-2438-47DF-AE99-89F35F9B54E8Q37626582-2A352536-3B37-4C8F-8A64-D6CBBDD272C2Q37680968-67B44D29-B6B7-4868-BBB4-D2BD17C34547Q37880875-0BFDFAFD-A484-48DB-BB55-2C3347D41CE4
P2860
Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Human organic anion transporti ...... pregnane X receptor activation
@ast
Human organic anion transporti ...... pregnane X receptor activation
@en
Human organic anion transporti ...... pregnane X receptor activation
@nl
type
label
Human organic anion transporti ...... pregnane X receptor activation
@ast
Human organic anion transporti ...... pregnane X receptor activation
@en
Human organic anion transporti ...... pregnane X receptor activation
@nl
prefLabel
Human organic anion transporti ...... pregnane X receptor activation
@ast
Human organic anion transporti ...... pregnane X receptor activation
@en
Human organic anion transporti ...... pregnane X receptor activation
@nl
P2093
P3181
P356
P1476
Human organic anion transporti ...... pregnane X receptor activation
@en
P2093
Allan W Wolkoff
Brenda F Leake
Richard B Kim
Rommel G Tirona
P3181
P356
10.1124/JPET.102.043026
P407
P577
2003-01-01T00:00:00Z